Epitome Therapeutics FlexCo

Epitome Therapeutics is developing a CRISPR-based platform that modulates gene activity without altering underlying DNA. It addresses diseases caused by insufficient expression of functional genes, where traditional therapies cannot properly restore gene levels due to short-lived gene activation, insufficient protein e

Epitome Therapeutics FlexCo is active in the advanced therapies space.

Profile

Epitome Therapeutics is developing a CRISPR-based platform that modulates gene activity without altering underlying DNA. It addresses diseases caused by insufficient expression of functional genes, where traditional therapies cannot properly restore gene levels due to short-lived gene activation, insufficient protein expression, and/or limited control of gene expression. The venture’s platform, CADENCE, offers precise, tunable activation […]

Epitome Therapeutics FlexCo is positioned in advanced therapies, a segment that rewards a clear, focused offering.

It is recorded at the Creative Destruction Lab alumni company stage.

Website: www.epitome-tx.com